Revance Therapeutics Inc (RVNC)
3.73
-0.11
(-2.86%)
USD |
NASDAQ |
Nov 22, 16:00
3.725
0.00 (0.00%)
Pre-Market: 20:00
Revance Therapeutics Revenue (Annual): 234.04M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 234.04M |
| December 31, 2022 | 132.56M |
| December 31, 2021 | 77.80M |
| December 31, 2020 | 15.32M |
| December 31, 2019 | 0.413M |
| December 31, 2018 | 3.729M |
| December 31, 2017 | 0.262M |
| Date | Value |
|---|---|
| December 31, 2016 | 0.30M |
| December 31, 2015 | 0.30M |
| December 31, 2014 | 0.383M |
| December 31, 2013 | 0.617M |
| December 31, 2012 | 0.717M |
| December 31, 2011 | 0.557M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
0.413M
Minimum
2019
234.04M
Maximum
2023
92.03M
Average
77.80M
Median
2021
Revenue (Annual) Benchmarks
| Recursion Pharmaceuticals Inc | 43.88M |
| Regeneron Pharmaceuticals Inc | 13.12B |
| MEI Pharma Inc | 65.30M |
| GlycoMimetics Inc | 0.01M |
| Anebulo Pharmaceuticals Inc | -- |